

29 **ABSTRACT**

30 Adenovirus based vectors are of increasing importance for wide ranging therapeutic applications. As
31 vaccines, vectors derived from human adenovirus species D serotypes 26 and 48 (HAdV-D26/48) are
32 demonstrating promising efficacy as protective platforms against infectious diseases. Significant
33 clinical progress has been made, yet definitive studies underpinning mechanisms of entry, infection,
34 and receptor usage are currently lacking. Here, we performed structural and biological analysis of
35 the receptor binding fiber-knob protein of HAdV-D26/48, reporting crystal structures, and modelling
36 putative interactions with two previously suggested attachment receptors, CD46 and Coxsackie and
37 Adenovirus Receptor (CAR). We provide evidence of a low affinity interaction with CAR, with
38 modelling suggesting affinity is attenuated through extended, semi-flexible loop structures,
39 providing steric hindrance. Conversely, *in silico* and *in vitro* experiments are unable to provide
40 evidence of interaction between HAdV-D26/48 fiber-knob with CD46, or with Desmoglein 2. Our
41 findings provide new insight to the cell-virus interactions of HAdV-D26/48, with important
42 implications for the design and engineering of optimised Ad-based therapeutics.

43 **ARTICLE**

44 Adenoviruses are increasingly important vectors for wide ranging therapeutic interventions, from
45 gene delivery and oncolytic agents to platforms for vaccine applications¹⁻³. As vaccine vectors, their
46 use clinically has been popularised by their excellent safety profile coupled with their ability to
47 induce robust cellular and humoral immunogenicity in humans⁴. Phylogenetically, the human
48 adenoviruses (HAdV's) are diverse, subdivided across 7 species, A-G⁵, based classically on serological
49 cross-reactivity, receptor usage, haemagglutination properties and, more recently, phylogenetic
50 sequence similarity^{6,7}.

51 Most experimental and clinical studies have focussed on the well-studied species C adenovirus,
52 HAdV-C5. Although potentially immunogenic, the efficacy of vaccines based on HAdV-C5 appears
53 hampered by high seroprevalence rates in humans, and enthusiasm for their use as clinical vaccine
54 platforms has been dampened by the well-publicised failure of the MERCK sponsored STEP vaccine
55 trial. This trial, to evaluate an HAdV-C5-based HIV vaccine encoding HIV gag/pol/nef antigens, was
56 abandoned due to apparent lack of efficacy upon 1st term analysis. The study also identified a non-
57 significant trend towards increased HIV acquisition in a specific high-risk, uncircumcised subset of
58 patients who also had high levels of baseline pre-existing neutralising antibodies to HAdV-C5^{8,9}. As a
59 result, attention has switched from HAdV-C5 based vectors towards the development of alternative
60 adenoviral serotypes with lower rates of pre-existing immunity. Most notably, vectors under
61 development include those based on species D serotypes including HAdV-D26, which has entered
62 Phase-III clinical trials as an Ebola vaccine and recently reported promising immunogenicity in an HIV
63 trial, or chimeric vectors utilising the hexon hyper variable regions (HVRs) of HAdV-D48 which have
64 undergone Phase-I evaluation as an HIV vaccine^{3,10-12}. However, despite extensive clinical advances
65 using these vaccine vectors we possess very limited knowledge of their basic biology, particularly
66 with regards to the determinants underpinning their tropism, mechanisms of cellular entry, and
67 receptor usage. In this study, we address these shortcomings through analysis of adenoviral diversity
68 in the context of their receptor binding, fiber proteins. Whilst adenoviruses are historically divided
69 into seven species, A-G, this may underestimate their diversity¹³⁻¹⁵. Phylogenetic examination of
70 human Adenovirus fiber proteins from different species shows deviation from the taxonomy
71 expected based upon whole genome taxonomy, likely due to recombination events as seen in other
72 Adenoviral proteins¹⁴. Here, we have sought to generate high resolution crystallographic structures
73 of the cellular interacting fiber-knob domains of species D Adenoviruses HAdV-D26 and HAdV-D48.
74 The fiber-knob is the receptor interacting domain of the fiber protein, one of three major capsid
75 proteins along with the hexon and penton base, as shown schematically in figure 1A.

76 In this study, we employ an integrative workflow utilising X-ray crystallography, *in silico* modelling,
77 and *in vitro* assays to dissect previous findings^{16,17} suggesting interactions by HAdV-D26 and HAdV-
78 D48 with Coxsackie and Adenovirus Receptor (CAR)^{5,18} and CD46 (Membrane Cofactor Protein,
79 MCP)^{16,17,19–21}. Utilising surface plasmon resonance (SPR), we also investigate the potential for HAdV-
80 D26 and HAdV-D48 to interact with Desmoglein 2. Our findings shed new light on the cell-virus
81 interactions of adenovirus and have potential implications for the design and engineering of
82 optimised HAdV-based therapeutics, both for vaccine applications and oncolytic development,
83 allowing us to minimise off-target or undesirable interactions *in vivo*.

84 RESULTS

85 Genetic variability in adenovirus fiber-knob protein

86 We generated phylogenetic trees of human adenovirus serotypes 1-56 which revealed greater
87 diversity in the fiber-knob domain (Fig. 1B) than might be expected based upon taxonomy of the
88 whole virus (Fig. 1C). These phylogenetic trees have been condensed to 70% bootstrap confidence
89 (500 bootstrap replicates) to exclude poorly supported nodes and display the projected diversity. A
90 full dendrogram showing to-scale branches is provided in Supplementary figure 1. In both
91 phylogenetic trees the adenoviruses divide into seven clades corresponding to the seven adenoviral
92 species, A-G. However, the tree based upon the fiber-knob domain (Fig. 1B) shows the species D
93 adenoviruses forming a greater number of sub-groups than in the whole genome tree suggesting
94 greater diversity in the receptors of this species than might be expected when comparing serotypes.
95 This may be the result of recombination events, as reported previously for other adenoviral
96 proteins^{13,15,22-24}. The opposite is observed in species B adenoviruses, where simpler groupings are
97 seen when analysing fiber-knob domain alignment than by whole genome analysis. When divided
98 into sub-species based on whole genome, they divide into species B1 and B2, but when the tree is
99 generated based on fiber-knob alone the species B viruses do not divide into similar groups. The
100 significance of this fiber-knob diversity is unclear, but it has previously been suggested that the
101 species B1/B2 designation may more closely represent the tissue tropism, than receptor usage^{25,26}.

102 We next calculated the amino acid variability at each position in the aligned adenoviral fiber-knob
103 sequences, which revealed regions of broad conservation corresponding to β -strands which make up
104 the main fold of the fiber-knob trimer (Fig. 1D). The positions corresponding to the β -strands of
105 HAdV-C5, as originally reported by Xia et al²⁷, are shown by arrows. Comparison shows that the
106 more N-terminal (A, B, and C) and C-terminal (I and J) β -strands have greater homology across the
107 adenoviral species than the other sheets. This may relate to the intervening loops between the less
108 tightly conserved β -strands (D, E, F, G, H) being more apical, a region which is often involved in
109 receptor interactions^{26,28-32}.

110 Structural analysis of HAdV-D26 and HAdV-D48 fiber-knob

111 To investigate diversity within the species D adenoviruses fiber-knob protein, recombinant, 6-His
112 tagged fiber-knob protein from HAdV-D26 and HAdV-D48 (hereafter referred to as HAdV-D26K and
113 HAdV-D48K) were generated, purified, and used to determine X-ray crystallographic structures of
114 HAdV-D26 (PDB: 6FJN) and HAdV-D48 (PDB: 6FJQ) at resolutions of 0.97Å and 2.7Å, respectively (Fig.

115 2A-D). Table 1 shows the data collection and refinement statistics for the crystallographic structures
116 generated in this study.

117 The monomers (Red, Green, Blue) form an anti-parallel β -barrel, typical of Adenoviral fiber-knob
118 protein, as described by Xia *et al* (PDB 1KNB)²⁷. Each monomer interacts with two neighbouring
119 copies to form homotrimer with 3-fold symmetry (Fig. 2B,D) and a highly stable interface
120 (Supplementary Figure 2A). Stability analysis using PISA (Protein Interactions, Surfaces and
121 Assemblies) software calculates the HAdV-D26 and HAdV-D48 trimers to have >20% lower interface
122 energy than that of HAdV-C5, indicative of a more stable interaction (Supplementary Figure 2A)
123 between the monomers of the HAdV-D26 and HAdV-D48 fiber-knobs.

124 As with the pan species analysis (Fig. 1D), variability of the aligned species D fiber-knobs (Fig. 2E)
125 confirmed that the β -strands comprising the hydrophobic core of the trimers are highly conserved,
126 with β -strands demonstrating a high degree of overlap in both spatial position and sequence
127 variability (Supplementary Figure 2B).

128 **Fiber-knob loops are stabilised by inter-loop interactions**

129 Particularly relevant to this study are the DG, GH, HI and IJ loops, linking the indicated strands
130 corresponding to those in the originally reported HAdV-C5 fiber-knob loops (Supplementary Figure
131 2B)²⁷. These loops have previously been shown to be critical in engagement of CD46 for Ad11, 35,
132 and 21³³⁻³⁶. Alignment of these loops with the corresponding loops of HAdV-C5 (species C, CAR
133 interacting), HAdV-B35 (species B, CD46 interacting), Ad11 (species B, CD46 interacting), and Ad37
134 (species D, CAR and Sialic acid/GD1a glycan interacting) reveals different topologies in these critical
135 receptor interacting regions (Fig. 3A)³⁵⁻³⁸. The HI loops of HAdV-D26K and HAdV-D48K are most
136 homologous to those of HAdV-B35K and HAdV-D37K respectively in terms of amino acid sequence
137 identity (Supplementary Figure 2B) and spatial alignment. The HAdV-D26K DG loop is most
138 homologous to HAdV-B35K but incorporates a three amino acid insertion, while HAdV-D48K DG loop
139 displays a differing and unique topology. The GH and IJ loops of HAdV-C5K, HAdV-D26K, HAdV-D37K,
140 and HAdV-D48K demonstrate similar spatial arrangements (though the similarity does not extend to
141 the sequence identity) but differ from the CD46 utilising HAd-B11K and HAdV-B35K.

142 The high-resolution structures obtained allowed us to robustly characterise the loops, seen in the
143 electron density maps (Fig. 3B, C). To assess loop flexibility and mobility, we assessed the B-factors
144 (also known as temperature factor), a measure of the confidence in the position of an atom which
145 can be used to infer flexibility. By assessing the B-Factors, the relative flexibility of the moieties of
146 interest can be inferred. While the apical domains of some loops demonstrated increased B-Factors

147 relative to the rest of the molecule, the loops' B-factors are surprisingly low (Fig. 3B, C), suggesting
148 that they may exhibit limited flexibility.

149 To investigate whether the different loop conformations were the product of flexibility, or restricted
150 mobility we investigated the inter-loop interactions in the HAdV-D26K and HAdV-D48K structures.
151 This analysis shows that the GH loop of HAdV-D26K (like those of HAdV-C5K, HAdV-D37K and HAdV-
152 D48K) does not extend directly away from the G and H β -sheets, but forms a β -hairpin (Fig. 3A, B)
153 that is maintained by seven polar contacts within the neighbouring IJ loop which restrict the loops'
154 orientation (Fig. 4A, Supplementary Figure 3A). Polar contacts were also observed at the apex of
155 several loops, notably the GH and CD loops (Fig. 4A, B). The IJ loops form fewer intramolecular polar
156 contacts but are stabilised by interactions with the adjacent CD and DG loops (Supplementary Figure
157 3C, D). These interactions retain the apical residues in a stable conformation, rather than leaving the
158 side chains fully labile.

159 The B-Factors of the HAdV-D48K DG loop were observed to be polarised about the hairpin, with the
160 outer face of the loop having higher B-Factors compared to the inner face (Fig.4C). This is likely the
161 result of polar contacts formed between Ser-307, Gln-308, Ala-309, and Leu-304 with Asp-359 and
162 Gln-357 of the opposing monomer stabilising the conformation of the DG loop. The proline rich
163 nature of this loop provides further rigidity (Supplementary Figure 2D).

164 Crystal contacts did not reveal any specific interactions between these DG-loops and neighbouring
165 non-trimer copies. We calculated the energy of interaction to be below the background threshold ($>$ -
166 3.0Kcalmol⁻¹) for all loops except DG. The DG-loop of HAdV-D26K is calculated to have an interaction
167 energy of -6.5Kcalmol⁻¹ in two separate stretches of this exceptionally long loop (Supplementary
168 Figure 4). Importantly, no strong contacts are found within the inter-monomer cleft.

169 Based on this analysis of the inter and intra-loop bonds we suggest that these adenoviral loops may
170 not be fully flexible variable regions, but organised receptor engagement motifs with carefully
171 evolved structures. This has direct implications for receptor engagement of these viruses, as the
172 loops govern previously characterised interactions with CAR and CD46, and are directly involved in
173 their pathogenicity^{25,33,39}.

174 ***In silico* evaluation of HAdV-D26/48K interaction with CAR**

175 Both CD46 and CAR have been proposed as primary attachment receptors for HAdV-D26 and HAdV-
176 D48^{16,17}. Previously generated crystal structures of HAdV-B11K in complex with full length CD46
177 (PDB: 3O8E), and HAd-D37K in complex with CAR-D1 domain (PDB: 2J12) reveal the loops to be
178 essential to receptor interactions⁴⁰. To investigate the ability of HAdV-D26K and HAdV-D48K to bind

179 these receptors we generated homology models by alignment of the new HAdV-D26K and HAdV-
180 D48K fiber-knob structures modelled with the existing fiber-knobs in complex with the receptor of
181 interest and performed energy minimisation to optimise the conformation to achieve the lowest
182 possible energy interface with which to analyse the interaction. We performed similar experiments
183 with the well described CAR and CD46 binding fiber-knob proteins of HAdV-C5 (PDB: 6HCN) and
184 HAdV-B35 (PDB: 2QLK), respectively, as controls.

185 Modelling of HAdV-D26K and HAdV-D48K in complex with the CAR-D1 domain revealed a region of
186 high homology with the CAR utilising HAdV-C5 fiber-knob, here after termed the α -interface (Fig.
187 5A). Sequence alignment with HAdV-C5K shows that many of the residues previously shown to be
188 critical for CAR interaction in HAdV-C5K are conserved in HAdV-D26K and HAdV-D48K (Fig. 5B),
189 including Ser-408, Pro-409, and Tyr-376³⁷. The same is true of residues predicted to interact with
190 CAR directly, such as Lys-417 (number is for HAdV-C5K). The residues predicted to form direct CAR
191 binding interactions for HAdV-C5K, HAdV-D26K, and HAdV-D48K are pictured in complex with the
192 maximum spatial occupancy of the energy minimised CAR-D1 (Fig. 5C). The high levels of homology
193 are seen to extend to the proteins' fold as well as the linear sequence.

194 Binding energies were calculated between the modelled fiber-knob proteins CAR, restricting the
195 calculation to only the α -interface to best model the conserved region. For the modelled complexes
196 a stable α -interface was predicted for all complexes modelled, albeit weaker for the known non-CAR
197 utilising HAdV-B35K (Fig.5D) which has lower sequence conservation with HAdV-C5K. However, the
198 interaction is complicated by a second CAR interface, termed the β -interface (Fig. 6A). The loops
199 forming the β -interface with CAR-D1 differ between HAdV-C5, HAdV-D26, and HAdV-D48 fiber-knob
200 (Fig. 6B). The shorter HAdV-C5K DG loop does not clash with the CAR-D1 surface, whereas the
201 extended HAdV-D26K DG loop forms a partial steric clash, with surface seen to clash with the aligned
202 CAR-D1, and HAdV-D48K DG loop is seen to form an even larger steric clash. Whilst the longer loop
203 of HAdV-D26K is expected to be more flexible than that of HAdV-C5K, the HAdV-D48K DG loop is
204 surprisingly stable due to the characteristics described (Fig.4C).

205 **Biological evaluation of HAdV-D26/48K interaction with CAR**

206 Our modelling studies indicate that the longer, inflexible DG loop of HAdV-D48K would be likely
207 sterically hinder the HAdV-D48K: CAR interaction at the β -interface to a greater extent than the
208 more modest inhibition of the smaller and more labile loop of HAdV-D26K, which in turn would
209 exhibit more inhibition of CAR binding than that of HAdV-C5K, where no steric inhibition is observed.
210 Competition inhibition assays using recombinant fiber-knob protein to inhibit antibody binding to
211 CAR receptor in CHO-CAR cells (which express CAR, while the parental cell line (CHO-K1) is

212 established to be non-permissive to adenovirus infection) support our observation (Fig. 6C). The IC_{50}
213 (the concentration of protein required to inhibit 50% of antibody binding) of HAdV-C5K is $7.0 \text{ ng}/10^5$
214 cells, while HAdV-D26K and HAdV-D48K demonstrate IC_{50} values 15.7 and 480 times higher at
215 $0.110 \mu\text{g}/10^5$ cells and $3.359 \mu\text{g}/10^5$ cells, respectively, reflecting their reduced ability to engage CAR.

216 Surface plasmon resonance (SPR) analysis indicates that HAdV-C5K binds strongly to CAR (Fig. 6D)
217 with a K_D of 0.76nM. HAdV-D26K and HAdV-D48K have lower overall affinities for CAR (Fig. 6E).
218 While the K_{Off} of the 3 fiber knob proteins (Fig. 6E) are similar, the K_{On} is fastest for HAdV-C5K, with
219 HAdV-D26K K_{On} being slower, and HAdV-D48K exhibiting the slowest K_{On} . This shows that the K_{On} -
220 the ability to form the initial interaction with the receptor - is the major limiting factor in the fiber
221 knobs overall affinity for CAR.

222 ***In silico* evaluation of HAdV-D26/48K interaction with CD46**

223 A similar approach was taken to model HAdV-D26K and HAdV-D48K in complex with CD46.
224 Alignments with the previously published HAdV-B11K-CD46 complex were generated and energy
225 minimised to obtain the lowest energy state of the complex^{34,41}. This interface utilises loops DG, GH,
226 HI and IJ to form a network of polar interactions with the CD46 Sc1 and Sc2 domains (Fig. 7A)³⁵.

227 When HAdV-B35K was modelled in complex with CD46, a network of polar contacts between HAdV-
228 B35K and CD46 was predicted (Fig. 7B) similar to that observed in the HAdV-B11K-CD46 complex
229 crystal structure, PDB: 3O8E (Fig. 7A)³⁴. Previously HAdV-B35K residues Phe-243, Arg-244, Tyr-260,
230 Arg-279, Ser-282, and Glu-302 (underlined in Fig.7C) have been implicated as key contact residues
231 for CD46 interaction, and are conserved in HAdV-B11K (highlighted in blue, Fig.7C)³⁶. Our modelling
232 suggests that conversely, HAdV-D26K and HAdV-D48K are predicted to form very few polar contacts
233 with CD46 with just 2 contacts predicted for HAdV-D26K (Fig. 7D) and 3 predicted for HAdV-D48K
234 (Fig. 7E). Furthermore, they do not share any of the critical CD46 binding residues which have been
235 reported previously (underlined, Fig. 7C) for HAdV-B11K and HAdV-B35K, or any of the predicted
236 interacting residues (blue highlight, Fig. 7C).

237 We again employed PISA to calculate the binding energy of the various modelled and energy
238 minimised fiber-knob CD46 complexes (Fig.8A). HAdV-B11K, the strongest known CD46 binding
239 adenovirus³³, was predicted to have the lowest binding energy reflecting its high stability interface,
240 with HAdV-B35 demonstrating a similar but slightly reduced binding energy. Conversely, HAdV-D26K
241 and HAdV-D48K are predicted to have lower binding energies, similar to that which may be expected
242 for random proteins passing in solution, indicating that any interaction between either the HAdV-
243 D26K, or HAdV-D48K with CD46 is unlikely⁴².

244 While still low compared to the known CD46 interacting HAdV-B11K and HAdV-B35K binding
245 energies, that for HAdV-C5K was higher than expected for a known non-CD46 interacting adenovirus
246 (Fig. 8A). Inspection of the model shows that this is due to the close proximity of the large HAdV-C5
247 HI loop to CD46 (Fig. 8B). The residues involved in the predicted interaction are not conserved in any
248 known CD46 interface and suggesting these are random interactions. Furthermore, interaction
249 between the DG loop and CD46 is integral to known CD46 binding interfaces and is prevented by the
250 HAdV-C5K HI loop laying between them (Fig. 8B).

251 **Biological evaluation of HAdV-D26/48K interaction with CD46**

252 Antibody competition inhibition assays in CHO-BC1 cells (CHO cells transduced to express the BC1
253 isoform of CD46) were used to test the predictions made by modelling (Fig. 8C). These data confirm
254 that recombinant HAdV-D26K and HAdV-D48K proteins are incapable of inhibiting antibody binding
255 to CD46 at any concentration tested (up to 2ng/cell), whilst the well-defined CD46 interacting HAdV-
256 B35K demonstrates strong inhibition, with a calculated IC_{50} of $0.003\mu\text{g}/10^5$ cells.

257 SPR analysis of the interaction between recombinant fiber-knob protein with CD46 confirms these
258 findings. The known CD46 utilising HAdV-B35K is seen to bind CD46 even at low concentration, while
259 HAdV-D48K shows no interaction (Fig. 8D). HAdV-D26K shows a very low affinity interaction with
260 CD46, however the kinetics are extremely fast making it impossible to measure an accurate $K_{On/Off}$ at
261 any of the concentrations measured, suggesting an unstable interface. The calculated K_D for HAdV-
262 D26K is seen to be more than 1.5×10^3 times lower than that of HAdV-B35K (Fig. 8E).

263 ***In silico* evaluation of HAdV-D26/48K interaction with DSG-2**

264 The third major protein receptor for human adenoviruses is Desmoglein 2 (DSG2), shown to enable
265 infection by HAdV-B3, B7, B11, and B14^{43,44}. Whilst we have not been able to model the interaction
266 of HAdV-D26 or D48 with DSG2, due to the lack of an available high-resolution complexed structure
267 at time of writing, we investigated the interaction by SPR analysis. HAdV-B3 is the best studied DSG2
268 binding adenovirus and showed binding in the μM range when tested by SPR (Fig.9A), however, no
269 binding was observed when the same experiment was run with HAdV-D26K or HAdV-D48K (Fig. 9B).

270

271 DISCUSSION

272 This study reveals the crystal structure of two adenovirus proteins critical to primary receptor
273 engagement, HAdV-D26 and HAdV-D48 fiber-knob, which are important viral vectors currently in
274 human clinical trials^{3,11,12}. Despite their advanced development, the field lacks fundamental
275 knowledge regarding the mechanisms of infection for these viral vector platforms. The work we
276 described here provides a combined crystallographic, *in silico*, and *in vitro* approach to investigate
277 adenovirus fiber-knob: receptor interactions with CAR and CD46, two receptors previously proposed
278 to be utilised by these viruses^{5,9,17}.

279 Analysis of the phylogenetic relationship between 56 Adenovirus serotypes, both whole genome and
280 fiber-knob domain alignment (Fig.1A), confirms diversification into the widely accepted seven
281 adenoviral species⁷. However, generating the phylogenetic tree with fiber-knob sequences, rather
282 than whole genomes, shows additional diversity, not revealed by the whole virus taxonomy.
283 Adenovirus species D breaks up into several additional sub-clades when focused on the fiber-knob,
284 suggesting greater receptor diversity than might be expected based on the whole virus phylogeny.
285 Similar observations have previously been made in species D hexon and penton¹³.

286 In contrast to species D, the phylogeny of species B adenoviruses, which are known to utilise
287 Desmoglein 2 and CD46 as primary receptors, is simplified when focused upon the fiber-knob,
288 indicating less diverse receptor usage^{39,43-45}. This simplification in comparison to the whole genomic
289 alignment implies that much of the species diversity must lay in other proteins. The E3 protein, for
290 example, is known to be highly diverse within species B adenoviruses, having previously been
291 exploited in the selection of the oncolytic (cancer killing) virus enadenotucirev, which is currently in
292 clinical trials^{13,46,47}.

293 That we see such opposing effects on the species B and D phylogenetic trees when focusing on the
294 fiber-knob, highlights the limitations of simple taxonomic approaches. The current Adenoviral
295 taxonomy is based on antibody neutralisation assays, which are limited by antibodies reliance on
296 surface accessible proteins in the capsid, and does not account for diversity in other viral proteins, as
297 the above suggests for species B. This supports a taxonomic proposal based upon viral genetics
298 rather than antibody neutralisation, as has previously been suggested^{13,48}.

299 Many studies on adenovirus neutralisation have focused upon neutralising antibodies (NAbs) which
300 bind to the hexon⁴⁹⁻⁵¹. Following intramuscular vaccination with non-replicating adenoviral vectors,
301 most NAbs are targeted to the hexon; a reflection of its high abundance and surface availability in
302 each viral capsid^{49,52}. However, during natural infection, many NAbs target the fiber protein⁵²,

303 presumably due to the abundance of fiber produced in the early stages of hAdV replication to loosen
304 cell-cell junctions and facilitate viral spread, prior to lysis and entry of large amounts of whole virus
305 to the blood stream⁵³. For individuals with pre-existing anti-adenovirus immunity derived from
306 natural infections, anti-fiber NABs are likely to limit the use of vectors with common adenovirus fiber
307 proteins by neutralisation of the viral vector prior to its therapeutic effect. Thus, for the
308 development of vectors to circumvent pre-existing anti-adenovirus immunity for therapeutic use
309 further exploration of this fiber protein diversity may be beneficial, as well as the on-going studies
310 using hexon HVR pseudotypes to circumvent anti-hexon immunity^{11,54}.

311 Analysis of the adenovirus loops (Fig.4, Supplementary Figure 3) reveals an intricate network of polar
312 interactions which stabilise their three-dimensional structures. These bonds appear to hold the
313 loops in a conformation which, in the case of HAdV-B11K and HAdV-B35K, facilitates receptor
314 binding. In the HAdV-D26 and HAdV-D48 fiber-knob structures presented in this study the loops are
315 also held in a stable conformation, though not one which enables CD46 interaction.

316 Modelling of HAdV-D26K/HAdV-D48K in complex with CD46 (Fig.7) suggested few contacts, and
317 interface energy calculations using these models predict a weak binding energy (Fig.8). SPR indicated
318 that HAdV-D26K has an affinity for CD46 that is approximately 1500x weaker than that of HAdV-
319 B35K (Fig.8D,E). Combined with the extremely fast kinetics, this is suggestive of a highly unstable
320 interface. HAdV-D48K showed no affinity for CD46 at all. This was confirmed by *in vitro* competition
321 inhibition assays, in which no tested quantity of recombinant fiber-knob was capable of inhibiting
322 antibody binding to CD46 (Fig.8C). These findings appear contradictory to previous studies which
323 suggest CD46 as the primary receptor for these viruses^{16,17}. Our findings improve knowledge of the
324 cell entry mechanisms of these viruses and the vectors derived from them, and do not diminish the
325 observed effectiveness of these vaccines. However, if CD46, a protein expressed on the surface of
326 all nucleated cells, is not the receptor for these viruses then it is as yet unknown what the primary
327 tissue tropism determinant is for these clinically significant viruses^{55,56}.

328 A similar methodology was applied to the interaction HAdV-D26K/HAdV-D48K with CAR. Inspection
329 of the modelled complexes (Fig.5) indicated a conserved α -interface enabling CAR binding in
330 adenovirus 5, 26, and 48, fiber knobs. However, the structure of the β -interface interaction appears
331 to indicate a mechanism modulating the fiber-knob's CAR affinity (Fig.6). When occupying the
332 intermonomer cleft in the conformation shown in figure 6B, the DG loops of HAdV-D26K and HAdV-
333 D48K are likely to inhibit CAR binding by steric hindrance, but if the loops were to shift into a
334 conformation which relieves this clash CAR binding could occur. Therefore, the ability of these
335 vectors to interact with CAR is likely a function of the steric hindrance provided by these loops,

336 reducing the ability of the fiber-knob domain to engage CAR in a permissive conformation. SPR
337 analysis supports this hypothesis (Fig.6D, E), where the larger the DG loop of the investigated fiber-
338 knob the slower the K_{On} .

339 The inter-loop contacts described in figure 4A, B, and Supplementary Figure 3, and the normalised B-
340 factors described in figure 6B will influence the molecular dynamics of the DG-loops. Loops which
341 can occupy a CAR inhibitory conformation but have fewer stabilising contacts, such as that of HAdV-
342 D26K (Supplementary Figure 3A, C), should be more permissive to CAR binding. While loops which
343 are less flexible and/or stabilised in a CAR inhibitory conformation, such as HAdV-D48K (Fig. 6B,
344 Supplementary Figure 3B, D) should result in a fiber-knob which is less able to bind CAR. This
345 hypothesis fits the competition inhibition studies shown in figure 6C, which demonstrate that HAdV-
346 D26K has an approximately ~15x lower affinity for CAR than HAdV-C5K, and HAdV-D48K has 500x
347 lower affinity.

348 Interestingly, the affinity of HAdV-D48K for CAR as measured by SPR is approximately 2x higher than
349 that for HAdV-D26K, due to the slower K_{Off} of HAdV-D48K (Fig.6E) which is in contrast with the IC_{50}
350 curves (Fig.6C) in which HAdV-D48K is observed to bind to CAR less strongly than HAdV-D26K. The
351 incongruity may be explained by the methodology. It is possible that the large fluid volume in the
352 wells during the inhibition assay (in comparison to the BIAcore microfluidics system), favoured
353 greater binding by HAdV-D26K due to its faster K_{On} , compared to HAdV-D48K. This discrepancy does
354 not alter the proposed model of CAR interaction, and seems to confirm the importance of the K_{On} ,
355 presumably mediated by the β -interface.

356 Species D adenoviruses have a large range of different DG loops (Supplementary Figure 5). Most
357 sequences have lengths equal to, or greater than, that of HAdV-D26K, making it plausible that they
358 too could modulate the fiber-knob interaction with CAR. However, the magnitude of this effect will
359 be dependent on the individual molecular dynamics of the DG-loops and its interactions with
360 adjacent residues.

361 Assuming this mechanism of CAR binding regulation is broadly applicable, it may have important
362 implications for adenoviral vector design. The presence of a high affinity receptor for the virus can
363 mask the low affinity CAR interaction, creating a hidden tropism only observed if the virus is forced
364 to rely upon it. Expression of CAR on human erythrocytes suggests the potential for sequestration of
365 virotherapies in the blood⁵⁷. CAR expression in lung epithelial tissues offers another site for potential
366 off target activity^{58,59}. Therefore, many virotherapies previously thought to be non-CAR binding
367 adenoviruses may in fact demonstrate weak CAR tropism, driving off target infections or resulting in
368 sequestration of the vector in tissues other than that target. This may not be of grave consequence

369 for non-replicating vectors, such as viral vaccines, but in vectors which rely upon controlled
370 replication in targeted tissues, such as oncolytic virotherapies, this could result in off-target
371 infection, dysregulated expression of therapeutic protein, and reduced delivery to the point of need.

372 DSG2 was also shown to be unable to bind HAdV-D26K or HAdV-D48K at any concentration by SPR. It
373 is notable that the K_D measured for the HAdV-B3K (66.9 μ M) is much lower than that measured
374 during the original investigation of DSG2 as an HAdV-B3K receptor (2.3 nM)⁴⁴. This is likely due to our
375 use of recombinant knob trimers, rather than the multivalent penton dodecahedrons.

376 The final, known, Adenovirus fiber-knob receptor, which has thus far not been addressed in this
377 study is sialic acid, as part of glycosylation motifs. Several Adenoviruses have been shown to bind to
378 sialylated glycans, including HAdV-D37^{32,38}, HAdV-G52^{30,60}, and Canine adenovirus serotype 2 (CAV-
379 2)⁵⁷. Each of these three viruses binds to sialic acid by different mechanisms (Supplementary Figure
380 6). Supplementary Figure 6 shows that HAdV-D26/48K do not share the sialic acid binding residues
381 found in HAdV-G52K or CAV-2 but do share the Tyr-142 and Lys-178 contact residues with HAdV-
382 D37K. Further, the HAdV-D37K contact residue Pro-147 is between the sialic acid and the main chain
383 oxygen which is functionally identical at the similar position in HAdV-D26/48K. Taken together, it
384 remains plausible that HAdV-D26/48K may be capable of binding sialic acid in an HAdV-D37K like
385 manner. However, binding does not equate to functional infection, as seen with HAdV-D19pK³² and
386 further studies are required to ascertain whether HAdV-D26/48 are capable of utilising sialic acid to
387 generate a productive infection. Further, HAdV-D37 was shown to require a specific glycosylation
388 motif (GD1a) in order form a functional infection, so any assessment of sialic acid as an adenoviral
389 receptor must be in the context of its glycan carrier³⁸.

390 The work undertaken in this study presents, for the first time, the crystal structures of the fiber-knob
391 domain protein of HAdV-D26 (PDB: 6FJN), and HAdV-D48 (PDB: 6FJQ) fiber-knob protein. In addition
392 we report a new crystal structure for HAdV-C5 fiber-knob protein (PDB: 6HCN) with improved
393 resolution compared to the existing structure (PDB: 1KNB)²⁷. We utilised these structures to
394 investigate the ability of these proteins to interact with the putative receptors, CAR and CD46, by an
395 integrative structural, *in silico*, and *in vitro* work flow. We demonstrate that HAdV-D26 and HAdV-
396 D48 fiber-knob domains have a weak ability to bind CAR, and negligible CD46 interaction, suggesting
397 that these viruses are unlikely to utilise these proteins as a primary receptor *in vivo*. Finally, we
398 showed that DSG2 is also unable to form a stable interaction in the context of SPR analysis. We
399 suggest that CAR binding is moderated by a previously unreported mechanism of steric inhibition
400 which may apply to other adenoviruses and demonstrate an *in silico* methodology capable of rapidly
401 predicting these interactions. These findings enhance our understanding of the virology of

402 adenovirus infection, and have direct implications for virotherapy vector design, which often rely
403 upon carefully controlled receptor tropisms to achieve specificity and efficacy^{9,18,28}.

404 **METHODS**

405 **Genome alignment and analysis of genetic diversity.**

406 Representative whole genomes (nucleotide) of adenoviral species 1-56 were selected from the
407 National Center for Biotechnology Information (NCBI), and aligned using the EMBL-EBI Clustal
408 Omega tool^{61,62}. Fiber-knob domain amino acid sequences were derived from the same genome
409 sequences, defined as the translated nucleotide sequence of the fiber protein (pIV) from the
410 conserved TLW hinge motif to the protein C-terminus, and aligned in the same manner as the whole
411 genomes. Phylogenetic relationships were inferred using the maximum likelihood method based
412 upon the Jukes Cantor model for the whole genome nucleotide analysis⁶³, and the Poisson
413 correction model for the fiber-knob amino acid analysis⁶⁴, using MEGA X software⁶⁵. Confidence was
414 determined by bootstrap analysis (500 replicates)⁶⁶ and trees displayed condensed at 70%
415 confidence (percentage confidence values shown at each node) where stated.

416 **Fiber-knob amino acid variability.**

417 Amino acid sequence variability scores were calculated from the Clustal omega aligned amino acid
418 sequences of the fiber-knob domains of either Adenoviruses 1-56, or only the species D
419 adenoviruses. Analysis was performed using the protein variability server (PVS), using a consensus
420 base sequence and the Wu-Kabat method⁶⁷.

421 **Generation of Recombinant Fiber-Knob protein.**

422 SG13009 *E.coli* harbouring pREP-4 plasmid and pQE-30 expression vector containing the fiber-knob
423 DNA sequence were cultured in 20ml LB broth with 100µg/ml ampicillin and 50µg/ml kanamycin
424 overnight from glycerol stocks made in previous studies^{18,68,69}. 1L of TB (Terrific Broth, modified,
425 Sigma-Aldrich) containing 100µg/ml ampicillin and 50µg/ml were inoculated with the overnight
426 *E.coli* culture and incubated at 37°C until they reached OD0.6. IPTG was then added to a final
427 concentration of 0.5mM and the culture incubated at 37°C for 4hrs. Cells were then harvested by
428 centrifugation at 3000g, resuspended in lysis buffer (50mM Tris, pH8.0, 300mM NaCl, 1% (v/v) NP40,
429 1mg/ml Lysozyme, 1mM β-mercaptoethanol), and incubated at room temperature for 30mins.
430 Lysate was clarified by centrifugation at 30,000g for 30mins and filtered through a 0.22µm syringe
431 filter (Millipore, Abingdon, UK). Clarified lysate was then loaded onto a 5ml HisTrap FF nickel affinity
432 chromatography column (GE) at 2.0ml/min and washed with 5 column volumes into elution buffer A
433 (50mM Tris [pH8.0], 300mM NaCl, 1mM β-mercaptoethanol). Protein was eluted by 30min gradient
434 elution from buffer A to B (buffer A + 400mM Imidazole). Fractions were analysed by reducing SDS-
435 PAGE, and Fiber-knob containing fractions further purified using a superdex 200 10/300 size

436 exclusion chromatography column (GE) in crystallisation buffer (10 mM Tris [pH 8.0] and 30 mM
437 NaCl). Fractions were analysed by SDS-PAGE and pure fractions concentrated by centrifugation in
438 Vivaspin 10,000 MWCO (Sartorius, Goettingen, Germany) preceding crystallisation.

439 **Competition Inhibition Assays.**

440 CHO cells expressing the appropriate receptor (CAR: CHO-CAR, or CD46: CHO-BC1) were seeded at a
441 density of 30,000 cells per well in a flat bottomed 96 well tissue culture plate and incubated at 37°C
442 overnight. Serial dilutions were made up in serum free RPMI-1640 to give a final concentration range
443 of 0.0001-100 µg/10⁵ cells of recombinant soluble knob protein. Cells were incubated on ice for
444 30mins, then washed twice with cold PBS. Fiber-knob dilutions were then added to the cells and
445 incubated on ice for 30mins. Cells were then washed twice in cold PBS and stained with the primary
446 CAR or CD46 antibody, Rmcb (Millipore; 05-644) or MEM-258 (Abcam; Ab789), respectively, to
447 complex receptors unbound by fiber-knob protein, and incubated for 1hr on ice. Cells were washed
448 twice further in PBS and incubated on ice for 1hr with Alexa-647 labelled goat anti-mouse F(ab')₂
449 (ThermoFisher; A-21237)^{18,68,69}. All antibodies were used at a concentration of 2µg/ml.

450 Samples were run in triplicate and analysed by flow cytometry on Attune NxT (ThermoFisher), and
451 analysed using FlowJo v10 (FlowJo, LLC) by gating sequentially on singlets, cell population, and Alexa-
452 647 positive cells. Total fluorescence (TF) was used as the measure of inhibition, rather than
453 percentage of fluorescent cells in the total population, to account for the presence of multiple
454 receptor copies per cell surface which can enable partial inhibition of antibody binding on the cell
455 surface. TF was defined as the percentage of Alexa-647 positive cells in the single cell population for
456 each sample and multiplied by the median fluorescent intensity (MFI) of the Alexa-647 positive
457 single cell population in each sample. Data points are the mean total fluorescence of three biological
458 replicates with error given as the standard deviation from the mean. IC₅₀ curves were fitted by non-
459 linear regression, and used to determine the IC₅₀ concentrations^{18,68,69}. CHO-CAR and CHO-BC1 cells
460 were originally derived by Bergelson *et al*⁷⁰, and Manchester *et al*⁷¹, respectively.

461 **Crystallisation and structure determination.**

462 Protein samples were purified into crystallisation buffer (10 mM TRIS [pH 8.0] and 30 mM NaCl). The
463 final protein concentration was approximately 7.5 mg/ml. Commercial crystallisation screen
464 solutions were dispensed into 96-well plates using an Art-Robbins Instruments Griffon dispensing
465 robot (Alpha Biotech, Ltd), in sitting-drop vapour-diffusion format. Drops containing 200nl of screen
466 solution and 200nl of protein solution were equilibrated against a reservoir of 60µl crystallisation
467 solution. The plates were sealed and incubated at 18°C.

468 Crystals of HAdV-C5K appeared in PACT *Premier* condition D04 (0.1 M MMT, pH 7.0, 20% PEG 1500),
469 within 1 to 7 days. Crystals of HAdV-D26K appeared within 1 to 7 days, in PACT *Premier* (Molecular
470 Dimensions, Suffolk, UK) condition A04 (0.1 M MMT [DL-Malic acid, MES monohydrate, Tris], pH 6.0,
471 25% PEG 1500. Crystals of HAdV-D48K appeared in PACT *Premier* condition D02 (0.1 M Bis-Tris-
472 propane, pH 6.5, 20% PEG 3350, 0.2M NaNO₃), within 2 weeks. Crystals were cryoprotected with
473 reservoir solution to which ethylene glycol was added at a final concentration of 25%. Crystals were
474 harvested in thin plastic loops and stored in liquid nitrogen for transfer to the synchrotron. Data
475 were collected at Diamond Light Source beamline I04, running at a wavelength of 0.9795Å. During
476 data collection, crystals were maintained in a cold air stream at 100°K. Dectris Pilatus 6M detectors
477 recorded the diffraction patterns, which were analysed and reduced with XDS, Xia2⁷², DIALS, and
478 Autoproc⁷³. Scaling and merging data was completed with Pointless, Aimless and Truncate from the
479 CCP4 package⁷⁴. Structures were solved with PHASER⁷⁵, COOT⁷⁶ was used to correct the sequences
480 and adjust the models, REFMAC5⁷⁷ was used to refine the structures and calculate maps. Graphical
481 representations were prepared with PyMOL⁷⁸. Reflection data and final models were deposited in
482 the PDB database with accession codes: HAdV-C5K, **6HCN**; HAdV-D26k, **6FJN**; and HAdV-D48k, **6JFQ**.
483 Full crystallographic refinement statistics are given in Supplementary Table 2; stereo images
484 depicting representative areas of the model and map are provided in Supplementary Figure 7.

485 **Modelling of fiber-knob ligand interactions.**

486 Fiber-knob proteins were modelled in complex with CAR or CD46 using the existing HAdV-D37K -
487 CAR liganded (PDB 2J12) or the HAdV-B11K - CD46 liganded (PDB 3O8E) structures, respectively, as a
488 template. Non-protein components and hydrogens were removed from the template model and the
489 fiber-knob protein of interest. The two fiber-knob proteins were then aligned with respect to their
490 C α chains, in such a way as to achieve the lowest possible RMSD. Models containing only the fiber-
491 knob protein of interest and the ligand were saved and subjected to energy minimisation, using the
492 YASARA self-parametrising energy minimisation algorithm as performed by the YASARA energy
493 minimisation server, and results were visualised in PyMol^{78,79}.

494 **Calculation of Interface Energy.**

495 Interface energies were calculated using QT-PISA using biological protein assemblies and excluding
496 crystallographic interfaces⁸⁰. Values are the mean of the three symmetrical interfaces in each trimer
497 and error is the standard deviation from the mean, any values above -3.0 kcalmol⁻¹ were considered
498 to be background as shown as a red dashed line on graphs⁴².

499 **Sequence alignments.**

500 Alignments were performed using the Clustal Omega multiple sequence alignment algorithm and
501 visualised with BioEdit^{61,62}.

502 **B-Factor Normalisation.**

503 Comparing order between different structures by comparing individual B-factors can be misleading.
504 Post-refinement B-factors relate to the Wilson B-factor, which can vary widely between data sets,
505 even from the same crystal preparation. A valid comparison between different structures can be
506 achieved by comparing normalised B-factors instead. Normalisation was performed by dividing
507 individual atomic B-factors by the average B-factor of the whole data set, quantifying the range of
508 internal flexibility in a structure. This normalised B- factor can then be compared between different
509 data sets.

510 **Surface Plasmon Resonance (SPR) analysis.**

511 Binding analysis was performed using a BIAcore 3000™ equipped with a CM5 sensor chip.
512 Approximately 5000 RU of CD46, CAR and DSG2 was attached to the CM5 sensor chip, using amine
513 coupling, at a slow flow-rate of 10 µL/min to ensure uniform distribution on the chip surface. A blank
514 flow cell was used as negative control surface on flow cell 1. All measurements were performed at
515 25°C in PBS buffer (Sigma, UK) at a flow rate of 30 µl/min. For equilibrium binding analysis, the
516 HAdV-D26K and HAdV-B3K fiber knob proteins were purified and concentrated to 367 and 3 µM
517 respectively. 5X 1:3 serial dilutions were prepared for each sample and injected over the relevant
518 sensor chip. The equilibrium binding constant (K_D) values were calculated assuming a 1:1 interaction
519 by plotting specific equilibrium-binding responses against protein concentrations followed by non-
520 linear least squares fitting of the Langmuir binding equation. For single cycle kinetic analysis, HAdV-
521 D26K, HAdV-D48K, HAdV-B35K, HAdV-C5K and HAdV-B3K were injected at a top concentration of
522 around 200 µM, followed by four injections using serial 1:3 dilutions. The K_D values were calculated
523 assuming Langmuir binding ($AB = B \times AB_{max} / (K_D + B)$) and the data were analysed using the kinetic
524 titration algorithm (BIAevaluation™ 3.1) Receptor proteins were obtained commercially, as follows:
525 Recombinant Human Desmoglein-2 Fc Chimera Protein, R&D systems, Catalogue number 947-DM-
526 100. Recombinant Human CXADR Fc Chimera Protein (CAR), R&D systems, Catalogue number 3336-
527 CX-050. Recombinant Human CD46 Protein (His Tag), Sino Biological, Catalogue number 12239-
528 H08H.

529 **Data Availability Statement.**

530 Macromolecular structures generated during this study have been deposited in wwPDB (worldwide
531 Protein Data Bank; <https://www.wwpdb.org/>), and have PDB ID's 6FJN, 6HCN, and 6FJQ. PDB ID's for
532 macromolecular structures utilised, but not generated in the course of this study, are as follows:
533 HAdV-B11K in complex with CD46, PDB 3O8E. HAdV-D37K in complex with CAR-D1, PDB 2J12. HAdV-
534 B35K, PDB 2QLK.

535 Genomic sequences from which fiber-knob domain sequences were determined, which have been
536 used in phylogenetic analysis, have the following NCBI accession numbers:
537 AC_000017|AF532578|X73487|AY803294|AB562586|AY601636|AF108105|GU191019|JQ326209|
538 AC_000007|JN226749|KF528688|FJ404771|JN226750|JN226751|JN226752|EF153474|JN226753|
539 FJ824826|JN226754|JN226755|AM749299|JN226756|JN226758|AY737797|AC_000019|GQ38408
540 0|JN226759|JN226760|KU162869|DQ315364|JN226761|JN226762|JN226763|JN226764|AY87564
541 8|JN226757|EF153473|DQ393829|AC_000008|AY737798|JN226765|DQ923122|AB605243|NC_01
542 2959|FJ643676|HM770721|HQ413315|AC_000018|DQ086466|JN226746|JN226747|AB448776|A
543 B448767|AJ854486|KF006344|

544 All other data pertaining to this manuscript are available from the authors upon request.

545 **Acknowledgments.**

546 ATB is supported by a Tenovus Cancer Care PhD studentship to ALP (reference PhD2015/L13). AG-W
547 was supported by a Life Sciences Research Network Wales (LSRNW) PhD studentship. JAD is
548 supported by a Cancer Research UK Biotherapeutics Drug Discovery Project Award to ALP (project
549 reference C52915/A23946). HU-K was supported by a Cancer Research Wales PhD studentship to
550 ALP. LC is funded by The HC Roscoe Grant 2016 from the British Medical Association Foundation for
551 Medical Research and by the National Institutes for Health (NIH)/National Institute of Allergy and
552 Infectious Diseases (NIAID) under CEIRS contract HHSN272201400008C. ALP and PJR are funded by
553 Higher Education Funding Council for Wales. The authors acknowledge the Diamond Light Source for
554 beamtime (proposal mx14843) and the staff of beamline I04 for assistance with diffraction data
555 collection. The authors acknowledge Johanne Pentier for technical assistance with SPR data
556 collection, as well as Aaron Wall and Anna Fuller for assistance with FPLC. The authors also
557 acknowledge Elmar Kreiger and the team who maintain the YASARA energy minimisation server, and
558 Pedro Reche and the Immunomedicine Group for maintenance of the Protein Variability Server.

559 **Author Contributions.**

560 ATB and ALP conceived and designed the study. Modelling of Protein-Protein interfaces,
561 phylogenetics, protein variability, and interface energy calculations, were performed by ATB. ATB

562 and AG-W performed crystallisation experiments. ATB, AG-W, and PJR, solved and refined
563 crystallographic structures, and analysed the resultant models. Competition inhibition studies were
564 performed by ATB with advice from LC. ATB and DKC performed SPR experiments. HU-K, JAD, and LC
565 provided DNA constructs and preliminary data. The manuscript was prepared by ATB and ALP, all
566 other authors reviewed, edited and approved the manuscript. The study was supervised by ALP.

567 **Competing Interests.**

568 The authors declare no competing interests.

569

570 **REFERENCES**

- 571 1. Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects - Full Text View -
572 ClinicalTrials.gov. Available at:
573 [https://clinicaltrials.gov/ct2/show/NCT02798406?term=adenovirus&recrs=a&cond=Glioblastoma](https://clinicaltrials.gov/ct2/show/NCT02798406?term=adenovirus&recrs=a&cond=Glioblastoma&rank=2)
574 [a&rank=2](https://clinicaltrials.gov/ct2/show/NCT02798406?term=adenovirus&recrs=a&cond=Glioblastoma&rank=2). (Accessed: 23rd September 2017)
- 575 2. A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2 - Full Text View - ClinicalTrials.gov.
576 Available at:
577 [https://clinicaltrials.gov/ct2/show/NCT03203421?term=adenovirus&recrs=a&cond=malaria&ra](https://clinicaltrials.gov/ct2/show/NCT03203421?term=adenovirus&recrs=a&cond=malaria&rank=2)
578 [nk=2](https://clinicaltrials.gov/ct2/show/NCT03203421?term=adenovirus&recrs=a&cond=malaria&rank=2). (Accessed: 23rd September 2017)
- 579 3. Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines
580 Ad26.ZEBOV and/or MVA-BN-Filo - Full Text View - ClinicalTrials.gov. Available at:
581 [https://clinicaltrials.gov/ct2/show/NCT02661464?term=adenovirus&recrs=a&cond=ebola&rank](https://clinicaltrials.gov/ct2/show/NCT02661464?term=adenovirus&recrs=a&cond=ebola&rank=1)
582 [=1](https://clinicaltrials.gov/ct2/show/NCT02661464?term=adenovirus&recrs=a&cond=ebola&rank=1). (Accessed: 23rd September 2017)
- 583 4. Lee, C. S. *et al.* Adenovirus-mediated gene delivery: Potential applications for gene and cell-
584 based therapies in the new era of personalized medicine. *Genes Dis.* **4**, 43–63 (2017).
- 585 5. Abbink, P. *et al.* Comparative Seroprevalence and Immunogenicity of Six Rare Serotype
586 Recombinant Adenovirus Vaccine Vectors from Subgroups B and D. *J. Virol.* **81**, 4654–4663
587 (2007).
- 588 6. Family - Adenoviridae. in *Virus Taxonomy* (eds. King, A. M. Q., Adams, M. J., Carstens, E. B. &
589 Lefkowitz, E. J.) 125–141 (Elsevier, 2012). doi:10.1016/B978-0-12-384684-6.00009-4
- 590 7. International Committee on Taxonomy of Viruses. *Virus taxonomy: classification and*
591 *nomenclature of viruses : sixth report of the International Committee on Taxonomy of Viruses.*
592 (Springer-Verlag, 1995).
- 593 8. Mast, T. C. *et al.* International epidemiology of human pre-existing adenovirus (Ad) type-5, type-
594 6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for
595 potential HIV vaccine trials. *Vaccine* **28**, 950–957 (2010).

- 596 9. Uusi-Kerttula, H., Hulin-Curtis, S., Davies, J. & Parker, A. L. Oncolytic Adenovirus: Strategies and
597 Insights for Vector Design and Immuno-Oncolytic Applications. *Viruses* **7**, 6009–6042 (2015).
- 598 10. Priddy, F. H. *et al.* Safety and Immunogenicity of a Replication-Incompetent Adenovirus Type 5
599 HIV-1 Clade B *gag/pol/nef* Vaccine in Healthy Adults. *Clin. Infect. Dis.* **46**, 1769–1781 (2008).
- 600 11. Baden, L. R. *et al.* First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing
601 HIV-1 Env (IPCAVD 002). *J. Infect. Dis.* **210**, 1052–1061 (2014).
- 602 12. Barouch, D. H. *et al.* Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-
603 blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-
604 19). *The Lancet* **392**, 232–243 (2018).
- 605 13. Robinson, C. M. *et al.* Molecular evolution of human adenoviruses. *Sci. Rep.* **3**, 1812 (2013).
- 606 14. Rux, J. J., Kuser, P. R. & Burnett, R. M. Structural and Phylogenetic Analysis of Adenovirus Hexons
607 by Use of High-Resolution X-Ray Crystallographic, Molecular Modeling, and Sequence-Based
608 Methods. *J. Virol.* **77**, 9553–9566 (2003).
- 609 15. Singh, G. *et al.* Overreliance on the Hexon Gene, Leading to Misclassification of Human
610 Adenoviruses. *J. Virol.* **86**, 4693–4695 (2012).
- 611 16. Teigler, J. E., Iampietro, M. J. & Barouch, D. H. Vaccination with Adenovirus Serotypes 35, 26,
612 and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus
613 Monkeys. *J. Virol.* **86**, 9590–9598 (2012).
- 614 17. Li, H. *et al.* Adenovirus Serotype 26 Utilizes CD46 as a Primary Cellular Receptor and Only
615 Transiently Activates T Lymphocytes following Vaccination of Rhesus Monkeys. *J. Virol.* **86**,
616 10862–10865 (2012).
- 617 18. Uusi-Kerttula, H. *et al.* Pseudotyped $\alpha\beta 6$ integrin-targeted adenovirus vectors for ovarian
618 cancer therapies. *Oncotarget* **7**, 27926–27937 (2016).
- 619 19. Camacho, Z. T., Turner, M. A., Barry, M. A. & Weaver, E. A. CD46-Mediated Transduction of a
620 Species D Adenovirus Vaccine Improves Mucosal Vaccine Efficacy. *Hum. Gene Ther.* **25**, 364–374
621 (2014).

- 622 20. Weaver, E. A. & Barry, M. A. Low Seroprevalent Species D Adenovirus Vectors as Influenza
623 Vaccines. *PLoS ONE* **8**, (2013).
- 624 21. Geisbert, T. W. *et al.* Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors
625 Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge. *J. Virol.*
626 **85**, 4222–4233 (2011).
- 627 22. Wang, Y. *et al.* Phylogenetic evidence for intratypic recombinant events in a novel human
628 adenovirus C that causes severe acute respiratory infection in children. *Sci. Rep.* **6**, 23014 (2016).
- 629 23. Ebner, K., Pinsker, W. & Lion, T. Comparative Sequence Analysis of the Hexon Gene in the Entire
630 Spectrum of Human Adenovirus Serotypes: Phylogenetic, Taxonomic, and Clinical Implications. *J.*
631 *Virology* **79**, 12635–12642 (2005).
- 632 24. Al Qurashi, Y. M. A., Alkhalaf, M. A., Lim, L., Guiver, M. & Cooper, R. J. Sequencing and
633 phylogenetic analysis of the hexon, fiber, and penton regions of adenoviruses isolated from AIDS
634 patients. *J. Med. Virol.* **84**, 1157–1165 (2012).
- 635 25. Pache, L., Venkataraman, S., Nemerow, G. R. & Reddy, V. S. Conservation of fiber structure and
636 CD46 usage by subgroup B2 adenoviruses. *Virology* **375**, 573–579 (2008).
- 637 26. Russell, W. C. Adenoviruses: update on structure and function. *J. Gen. Virol.* **90**, 1–20 (2009).
- 638 27. Xia, D., Henry, L. J., Gerard, R. D. & Deisenhofer, J. Crystal structure of the receptor-binding
639 domain of adenovirus type 5 fiberprotein at 1.7 Å resolution. *Structure* **2**, 1259–1270 (1994).
- 640 28. Baker, A. T., Aguirre-Hernández, C., Halldén, G. & Parker, A. L. Designer Oncolytic Adenovirus:
641 Coming of Age. *Cancers* **10**, 201 (2018).
- 642 29. Amoureux, M.-C. *et al.* Polysialic Acid Neural Cell Adhesion Molecule (PSA-NCAM) is an adverse
643 prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. *BMC Cancer*
644 **10**, 91 (2010).
- 645 30. Lenman, A. *et al.* Human Adenovirus 52 Uses Sialic Acid-containing Glycoproteins and the
646 Coxsackie and Adenovirus Receptor for Binding to Target Cells. *PLOS Pathog.* **11**, e1004657
647 (2015).

- 648 31. Arnberg, N. *et al.* Adenovirus Type 37 Binds to Cell Surface Sialic Acid Through a Charge-
649 Dependent Interaction. *Virology* **302**, 33–43 (2002).
- 650 32. Arnberg, N., Edlund, K., Kidd, A. H. & Wadell, G. Adenovirus Type 37 Uses Sialic Acid as a Cellular
651 Receptor. *J. Virol.* **74**, 42–48 (2000).
- 652 33. Cupelli, K. *et al.* Structure of Adenovirus Type 21 Knob in Complex with CD46 Reveals Key
653 Differences in Receptor Contacts among Species B Adenoviruses. *J. Virol.* **84**, 3189–3200 (2010).
- 654 34. Persson, B. D. *et al.* Structure of the Extracellular Portion of CD46 Provides Insights into Its
655 Interactions with Complement Proteins and Pathogens. *PLOS Pathog.* **6**, e1001122 (2010).
- 656 35. Persson, B. D. *et al.* Adenovirus type 11 binding alters the conformation of its receptor CD46.
657 *Nat. Struct. Mol. Biol.* **14**, 164–166 (2007).
- 658 36. Wang, H. *et al.* Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob.
659 *J. Virol.* **81**, 12785–12792 (2007).
- 660 37. Kirby, I. *et al.* Identification of Contact Residues and Definition of the CAR-Binding Site of
661 Adenovirus Type 5 Fiber Protein. *J. Virol.* **74**, 2804–2813 (2000).
- 662 38. Nilsson, E. C. *et al.* The GD1a glycan is a cellular receptor for adenoviruses causing epidemic
663 keratoconjunctivitis. *Nat. Med.* **17**, 105–109 (2011).
- 664 39. Fleischli, C. *et al.* Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on
665 the membrane cofactor protein CD46 receptor. *J. Gen. Virol.* **88**, 2925–2934 (2007).
- 666 40. Seiradake, E., Lortat-Jacob, H., Billet, O., Kremer, E. J. & Cusack, S. Structural and Mutational
667 Analysis of Human Ad37 and Canine Adenovirus 2 Fiber Heads in Complex with the D1 Domain
668 of Coxsackie and Adenovirus Receptor. *J. Biol. Chem.* **281**, 33704–33716 (2006).
- 669 41. Krieger Elmar, Koraimann Günther & Vriend Gert. Increasing the precision of comparative
670 models with YASARA NOVA—a self-parameterizing force field. *Proteins Struct. Funct.*
671 *Bioinforma.* **47**, 393–402 (2002).

- 672 42. Jensen, J. H. Predicting accurate absolute binding energies in aqueous solution: thermodynamic
673 considerations for electronic structure methods. *Phys. Chem. Chem. Phys.* **17**, 12441–12451
674 (2015).
- 675 43. Vassal-Stermann, E. *et al.* Mapping of Adenovirus of serotype 3 fibre interaction to desmoglein 2
676 revealed a novel ‘non-classical’ mechanism of viral receptor engagement. *Sci. Rep.* **8**, (2018).
- 677 44. Wang, H. *et al.* Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. *Nat. Med.*
678 **17**, 96–104 (2011).
- 679 45. Segerman, A., Arnberg, N., Erikson, A., Lindman, K. & Wadell, G. There are two different species
680 B adenovirus receptors: sBAR, common to species B1 and B2 adenoviruses, and sB2AR,
681 exclusively used by species B2 adenoviruses. *J. Virol.* **77**, 1157–1162 (2003).
- 682 46. Kuhn, I. *et al.* Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon
683 Cancer. *PLOS ONE* **3**, e2409 (2008).
- 684 47. Illingworth, S. *et al.* Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-
685 Specific Oncolytic Adenovirus. *Mol. Ther. Oncolytics* **5**, 62–74 (2017).
- 686 48. HAdV Working Group, <http://hadvwg.gmu.edu/>.
- 687 49. Bradley, R. R., Lynch, D. M., Iampietro, M. J., Borducchi, E. N. & Barouch, D. H. Adenovirus
688 serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural
689 infection. *J. Virol.* **86**, 625–629 (2012).
- 690 50. Bradley, R. R. *et al.* Adenovirus Serotype 5-Specific Neutralizing Antibodies Target Multiple
691 Hexon Hypervariable Regions. *J. Virol.* **86**, 1267–1272 (2012).
- 692 51. Ma, J. *et al.* Manipulating Adenovirus Hexon Hypervariable Loops Dictates Immune
693 Neutralisation and Coagulation Factor X-dependent Cell Interaction In Vitro and In Vivo. *PLoS*
694 *Pathog.* **11**, (2015).
- 695 52. Parker, A. L. *et al.* Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene
696 transfer. *J. Virol.* **83**, 479–483 (2009).

- 697 53. Walters, R. W. *et al.* Adenovirus Fiber Disrupts CAR-Mediated Intercellular Adhesion Allowing
698 Virus Escape. *Cell* **110**, 789–799 (2002).
- 699 54. Keele, B. F. *et al.* Adenovirus prime, Env protein boost vaccine protects against neutralization-
700 resistant SIVsmE660 variants in rhesus monkeys. *Nat. Commun.* **8**, 15740 (2017).
- 701 55. Andrews, P. W. *et al.* A human cell-surface antigen defined by a monoclonal antibody and
702 controlled by a gene on human chromosome 1. *Ann. Hum. Genet.* **49**, 31–39 (1985).
- 703 56. Uhlen, M. *et al.* A pathology atlas of the human cancer transcriptome. *Science* **357**, eaan2507
704 (2017).
- 705 57. Seiradake, E. *et al.* The Cell Adhesion Molecule “CAR” and Sialic Acid on Human Erythrocytes
706 Influence Adenovirus In Vivo Biodistribution. *PLOS Pathog.* **5**, e1000277 (2009).
- 707 58. Cohen, C. J. *et al.* The coxsackievirus and adenovirus receptor is a transmembrane component of
708 the tight junction. *Proc. Natl. Acad. Sci.* **98**, 15191–15196 (2001).
- 709 59. Awasthi, V., Meinken, G., Springer, K., Srivastava, S. C. & Freimuth, P. Biodistribution of
710 Radioiodinated Adenovirus Fiber Protein Knob Domain after Intravenous Injection in Mice. *J.*
711 *Viro.* **78**, 6431–6438 (2004).
- 712 60. Lenman, A. *et al.* Polysialic acid is a cellular receptor for human adenovirus 52. *Proc. Natl. Acad.*
713 *Sci.* 201716900 (2018). doi:10.1073/pnas.1716900115
- 714 61. Sievers, F. *et al.* Fast, scalable generation of high-quality protein multiple sequence alignments
715 using Clustal Omega. *Mol. Syst. Biol.* **7**, 539–539 (2011).
- 716 62. Li, W. *et al.* The EMBL-EBI bioinformatics web and programmatic tools framework. *Nucleic Acids*
717 *Res.* **43**, W580-4 (2015).
- 718 63. Jukes, T. H. & Cantor, C. R. Evolution of Protein Molecules. in *Mammalian Protein Metabolism*
719 21–132 (Elsevier, 1969). doi:10.1016/B978-1-4832-3211-9.50009-7
- 720 64. Zuckerkandl, E. & Pauling, L. Evolutionary Divergence and Convergence in Proteins. in *Evolving*
721 *Genes and Proteins* (eds. Bryson, V. & Vogel, H. J.) 97–166 (Academic Press, 1965).
722 doi:10.1016/B978-1-4832-2734-4.50017-6

- 723 65. Kumar, S., Stecher, G., Li, M., Knyaz, C. & Tamura, K. MEGA X: Molecular Evolutionary Genetics
724 Analysis across Computing Platforms. *Mol. Biol. Evol.* **35**, 1547–1549 (2018).
- 725 66. Felsenstein, J. CONFIDENCE LIMITS ON PHYLOGENIES: AN APPROACH USING THE BOOTSTRAP.
726 *Evol. Int. J. Org. Evol.* **39**, 783–791 (1985).
- 727 67. Garcia-Boronat, M., Diez-Rivero, C. M., Reinherz, E. L. & Reche, P. A. PVS: a web server for
728 protein sequence variability analysis tuned to facilitate conserved epitope discovery. *Nucleic
729 Acids Res.* **36**, W35–W41 (2008).
- 730 68. Coughlan, L. *et al.* Retargeting Adenovirus Serotype 48 Fiber Knob Domain by Peptide
731 Incorporation. *Hum. Gene Ther.* **25**, 385–394 (2014).
- 732 69. Coughlan, L. *et al.* In Vivo Retargeting of Adenovirus Type 5 to $\alpha\beta 6$ Integrin Results in Reduced
733 Hepatotoxicity and Improved Tumor Uptake following Systemic Delivery. *J. Virol.* **83**, 6416–6428
734 (2009).
- 735 70. Bergelson, J. M. *et al.* Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses
736 2 and 5. *Science* **275**, 1320–1323 (1997).
- 737 71. Manchester, M., Liszewski, M. K., Atkinson, J. P. & Oldstone, M. B. Multiple isoforms of CD46
738 (membrane cofactor protein) serve as receptors for measles virus. *Proc. Natl. Acad. Sci.* **91**,
739 2161–2165 (1994).
- 740 72. Winter, G., Lobley, C. M. C. & Prince, S. M. Decision making in xia2. *Acta Crystallogr. D Biol.*
741 *Crystallogr.* **69**, 1260–1273 (2013).
- 742 73. Vonrhein, C. *et al.* Data processing and analysis with the autoPROC toolbox. *Acta Crystallogr. D*
743 *Biol. Crystallogr.* **67**, 293–302 (2011).
- 744 74. Dodson, E. J., Winn, M. & Ralph, A. [32] Collaborative computational project, number 4:
745 Providing programs for protein crystallography. in *Methods in Enzymology* **277**, 620–633
746 (Academic Press, 1997).
- 747 75. McCoy, A. J. *et al.* Phaser crystallographic software. *J. Appl. Crystallogr.* **40**, 658–674 (2007).

- 748 76. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta Crystallogr. D*
749 *Biol. Crystallogr.* **60**, 2126–2132 (2004).
- 750 77. Murshudov, G. N. *et al.* REFMAC5 for the refinement of macromolecular crystal structures. *Acta*
751 *Crystallogr. D Biol. Crystallogr.* **67**, 355–367 (2011).
- 752 78. Schrödinger, LLC. The PyMOL Molecular Graphics System, Version 2.0.
- 753 79. Krieger, E. *et al.* Improving physical realism, stereochemistry, and side-chain accuracy in
754 homology modeling: Four approaches that performed well in CASP8. *Proteins Struct. Funct.*
755 *Bioinforma.* **77**, 114–122 (2009).
- 756 80. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. *J. Mol.*
757 *Biol.* **372**, 774–797 (2007).
- 758

759 **Figure legends**

760 **Figure 1: Phylogenetic analysis of adenoviruses mapped by whole genome and fiber-knob domain.**

761 A diagrammatic representation of the adenoviral major capsid proteins show the icosahedral capsid
762 structure with the Hexon (orange) comprising the facets, pentons (green) at the vertices, from which
763 the fiber proteins (fiber-shaft in light blue, fiber-knob in dark blue) protrude (A). Condensed
764 maximum likelihood trees (percentage confidence shown by numbers next to nodes) were
765 generated from alignments of fiber-knob domain amino acid sequences of adenoviruses 1-56 (B) or
766 whole genome NT sequences (C). Adenoviruses divide into 7 subspecies, as denoted in the key,
767 regardless of alignment used, but the species D adenoviruses divide into additional sub-species
768 when determined by fiber-knob alignment, for readability simple nomenclature is used, all are
769 human adenovirus. Numbers next to nodes denote confidence. Wu-Kabat variability analysis of the
770 Clustal omega aligned fiber-knob domains amino acid sequences of adenoviruses 1-56 (D) reveals
771 regions of low amino acid variability corresponding to beta-sheets. The locations of HAdV-C5 β -
772 strands, as described by Xia et al (1995), are aligned to the structure and shown by arrows, the
773 corresponding positions are coloured in red.

774 **Figure 2: Overview of the HAdV-D26 and HAdV-D48 fiber-knob protein structures.** The surface
775 representation of the trimeric HAdV-D26K (PDB 6FJN) biological assembly is shown side-on with the
776 cartoon representation shown for the nearest monomer (A) and the top-down view of the same
777 HAdV-D26K trimer, as it would appear looking towards the virion, is seen as a cartoon
778 representation (B), with each monomer coloured in Red, Green, or Blue with the hypervariable loops
779 extending between the β -strands (Dark blue) coloured as follows: AB-Green, BC – Purple, CD –
780 Brown, DE – Orange, DG – Red, EG – Pink, GH – Purple, HI – Yellow, IJ – Light Blue. The HAdV-D48K
781 (PDB 6FJQ) trimer is shown similarly (C,D). The Wu-Kabat variability plot of the fiber-knob domains
782 of species D adenoviruses shows regions of low variability (E) with the locations of the HAdV-D48K β -
783 strands shown by arrows above the graph, and the positions coloured blue, or red when the position
784 is a β -strand in both HAdV-D26K and HAdV-D48K.

785 **Figure 3: Comparison of HI, DG, GH, and IJ loops of adenoviruses used in this study.** The
786 hypervariable loops of HAdV-D26K (Green) and HAdV-D48K (Cyan) relevant to this study (HI, DG, GH,
787 and IJ) are shown in the context of the control virus fiber-knob domains, HAdV-C5K (Orange), Ad11K
788 (Yellow), HAdV-B35K (Pink), and Ad37K (Purple). The electron density achieved in the loops of HAdV-
789 D26K (B) and HAdV-D48K (C) are shown as mesh. The fitted residues are seen as stick
790 representations, with oxygen and nitrogen atoms coloured red and blue, respectively and other

791 atoms coloured according to their relative B-factors with warmer colours indicating higher B-factor
792 values.

793 **Figure 4: Hypervariable loop conformations and contacts residues.** The residues comprising the
794 indicated loops of HAdV-D26K (A) and HAdV-D48K (B) are shown diagrammatically with numbers
795 indicating the start and end residues of each loop depicted. The network of intraloop polar
796 interactions is shown by solid lines (one polar bond), and dashed lines (two polar bonds, colour
797 variations are only for ease of viewing) between interacting residues, similar interloop bonds are
798 also present as visualised in Supplementary Figure 2. Residues forming part of a helical motif are
799 shaded in blue. The HAdV-D48K DG-loop is seen to form contacts to the opposing monomer across
800 the inter-monomeric cleft (C). The labelled residues forming polar contacts (shown as sticks) are
801 coloured by relative B-factor, with warmer colours indicating higher relative B-factors, as is the
802 cartoon representation of the loop. The opposing HAdV-D48K monomer is seen as a ribbon
803 representation of the carbon- α chain in cyan and the surface of the HAdV-D48K trimer seen as a
804 semi-transparent grey surface.

805 **Figure 5: Modelling of the HAdV-D26K and HAdV-D48K interaction with CAR at the α -interface.** The
806 α -interface region is shown by the box on the structural alignment of HAdV-C5K (Orange), 26K
807 (Green), and 48K (Cyan) fiber-knob domain crystal structures in complex with CAR-D1 domain (Grey)
808 as determined by homology alignment to the previously reported Ad37K CAR-D1 structure (PDB:
809 2J12) (A). The aligned amino acid sequence of the investigated fiber-knobs (B) and the predicted α -
810 interface forming CAR-D1 binding residues are highlighted in blue, with the underlined residues
811 representing the HAdV-C5K amino acids shown by Kirby *et al* (2000)³⁷ to be important for CAR
812 interaction. Conservation of key residues can be seen between HAdV-C5K, HAdV-D26K, and HAdV-
813 D48K fiber-knobs. This conservation is visualised, with the contact residues comprising the α -
814 interface with HAdV-C5K, 26K, and 48K shown as sticks in complex with the energy minimised CAR-
815 D1 domain (Grey), shown as the surface of the maximum spatial occupancy of the aligned CAR-D1
816 monomers from each of the energy minimised models in complex with HAdV-C5K, 26K, and 48K
817 fiber-knobs (C). (D) Plots the predicted binding energy of the energy minimised fiber-knob proteins
818 to CAR-D1 complex in the α -interface, only. Lower binding energy indicates a more stable interface
819 with the red line depicting 3.0 KcalMol⁻¹, which can be considered background. n=3, where each
820 calculation is an independent fiber-knob: CAR interface, error bars indicate mean \pm SD.

821 **Figure 6: Modelling of the HAdV-D26K and HAdV-D48K interaction with CAR at the β -interface.** The
822 β -interface region is shown by the box on the structural alignment of HAdV-C5K (Orange), 26K
823 (Green), and 48K (Cyan) fiber-knob domain crystal structures in complex with CAR-D1 domain (Grey)

824 as determined by homology alignment to the previously reported Ad37K CAR-D1 structure (PDB:
825 2J12) (A). A dot surface shows the surface of HAdV-C5K, 26K, and 48K DG-loops in the inter-
826 monomer cleft (B). The boxes denote the maximum B-factor of the corresponding loops, which are
827 shown as putty representations with thicker regions indicating higher relative B-factors, from which
828 we can infer the relative stability of the loops. Antibody competition inhibition assay (C) shows the
829 relative inhibitory ability of the HAdV-C5, 35, 26, and 48, fiber-knob domains in CAR expressing CHO-
830 CAR cells, with the calculated IC_{50} values shown in boxes. $n=3$ biological replicates. Surface Plasmon
831 Resonance (SPR) traces are shown by coloured lines, and the fitted curves by black lines (D). The
832 calculated binding coefficients On rate (K_{On}), Off rate (K_{Off}), and Dissociation coefficient (K_D) are given
833 in the table (E). IC_{50} curves are fitted by non-linear regression. Error bars represent standard
834 deviation of 3 biological replicates. Error bars indicate mean \pm SD.

835 **Figure 7: Modelling of the HAdV-D26K and HAdV-D48K with CD46.** Red dashes show contacts
836 between the energy minimised crystal structure of CD46 SC1 and SC2 domains (grey cartoon) and
837 Ad11K in complex (PDB 3O8E). The known CD46 interacting fiber-knob, HAdV-B35K (purple), is
838 aligned to the above crystal structure and energy minimised (B). Amino acid sequence alignment of
839 the tested fiber-knob proteins (C) shows conservation of residues previously shown by Wang *et al*
840 (2007) to be key to CD46 binding (underlined) between the known CD46 binding fiber-knobs, Ad11K
841 and HAdV-B35K. Residues highlighted in blue are predicted to form direct contacts with CD46 in the
842 energy minimised models. Similar alignments to that performed with HAdV-B35K are shown for
843 HAdV-D26K (Green - D) and HAdV-D48K (Cyan - E). In all models red dashes indicate polar contacts
844 between the residues shown as stick representations.

845 **Figure 8: Binding energetics and affinities of HAdV-D26K and HAdV-D48K with CD46.** Calculation of
846 the predicted binding energies for the energy minimised fiber-knob: CD46 models are compared on
847 the bar chart (A), lower $Kcalmol^{-1}$ values indicate a stronger interaction, the red line at $3.0 KcalMol^{-1}$,
848 denotes an interface energy which can be considered negligible (random proteins passing in
849 solution), $n=3$, where each calculation is an independent fiber-knob: CD46 interface. The HI loop
850 (red) of the HAdV-C5 fiber-knob (orange) is seen to extend between CD46 (grey) and the DG loop
851 (B). The antibody competition inhibition assay (C) shows the relative inhibitory ability of the HAdV-
852 C5, HAdV-B35, HAdV-D26, and HAdV-D48 fiber-knob domains in CD46 expressing CHO-BC1 cells,
853 with the calculated IC_{50} values shown in boxes. $n=3$ biological replicates. Surface Plasmon Resonance
854 (SPR) traces are shown by coloured lines, and the fitted curves by black lines (D). The calculated
855 binding coefficients On rate (K_{On}), Off rate (K_{Off}), and Dissociation coefficient (K_D) are given in the
856 table (E), nm (not measured) indicates that the kinetics were too fast to measure, nb denotes no

857 binding. IC_{50} curves are fitted by non-linear regression. Error bars represent standard deviation of 3
858 biological replicates. Error bars indicate mean \pm SD.

859 **Figure 9: Desmoglein 2 is unlikely to be a receptor for HAdV-D26K or HAdV-D48K.** The dissociation
860 constant was calculated for HAdV-B3K binding to DSG2, but kinetics were too fast to determine K_{on}
861 or K_{off} (A), the K_D curve is shown for HAdV-B3K while HAdV-D26K and HAdV-D48K are seen to form
862 no interaction with DSG2 (B). nm (not measured) indicates that the kinetics were too fast to
863 measure, nb denotes no binding.

864

865

866 **Table 1: Data collection and refinement statistics (molecular replacement)**

	Ad26FK	Ad5FK	Ad48FK
Data collection			
Space group	P 2 ₁ 3	P 2 ₁ 2 ₁ 2	P4 ₃ 32
Cell dimensions			
<i>a</i> , <i>b</i> , <i>c</i> (Å)	86.01,86.01,86.01	102.16,102.44,77.01	145.18,145.18,145.18
α , β , γ (°)	90.0,90.0,90.0	90.0,90.0,90.0	90.0,90.0,90.0
Resolution (Å)	0.97-60.82 (0.97-1.00)	1.49-61.56(1.49-1.53)	2.91-83.82(2.91-2.99)
<i>R</i> _{sym} or <i>R</i> _{merge}	0.043 (0.745)	0.134 (1.838)	0.125 (302.6)
<i>I</i> / σ <i>I</i>	27.3 (0.7)	7.1 (0.7)	22.2 (1.7)
Completeness (%)	94.9 (43.9)	99.8 (99.9)	100.0 (0.705)
Redundancy	16.7 (1.6)	6.6 (6.3)	41.2 (41.4)
Refinement			
Resolution (Å)	0.97-60.82	1.49-61.56	2.91-83.82
No. reflections	112,612	125,479	11,371
<i>R</i> _{work} / <i>R</i> _{free}	18.2/19.5	21.1/23.3	20.1/29.1
No. atoms	1,811	4,825	3,117
Protein	1,579	4,395	3,091
Ligand/ion	8	21	20
Water	224	409	6
<i>B</i> -factors	16.0	34.0	87.0
Protein	15.8	33.6	94.2
Ligand/ion	29.3	35.7	129.5
Water	23.9	42.9	61.0
R.m.s. deviations			
Bond lengths (Å)	0.025	0.011	0.019
Bond angles (°)	2.339	1.534	2.293

867 *One crystal was used for each dataset.

868 *Values in parentheses are for highest-resolution shell.



869

870


871

Figure 2 HAdV-D26 Fiber-Knob Domain (6FJN)

A




B




HAdV-D48 Fiber-Knob Domain (6FJQ)

C



D



E




Figure 3




Figure 4








Figure 6




A




B



D



C



E

	K_{on} ($M^{-1} s^{-1}$)	K_{off} (s^{-1})	K_D (μM)
HAdV-C5K	2×10^6	0.0016	0.00076
HAdV-D26K	3.4×10^2	0.0074	21
HAdV-D48K	2.5×10^2	0.0024	9.3

Figure 7




Figure 8




Figure 9

A

	K_{on} ($M^{-1} s^{-1}$)	K_{off} (s^{-1})	K_D (μM)
HAdV-B3K	nm	nm	66.9
HAdV-D26K	nb	nb	No binding
HAdV-D48K	nb	nb	No binding

B

